Dougados, Maxime
Kiltz, Uta
Kivitz, Alan
Pavelka, Karel
Rohrer, Susanne
McCreddin, Suzanne
Quebe-Fehling, Erhard
Porter, Brian
Talloczy, Zsolt
Clinical trials referenced in this document:
Documents that mention this clinical trial
THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2217
SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis
https://doi.org/10.1136/annrheumdis-2018-eular.4474
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials
https://doi.org/10.1007/s00296-021-05044-6
FRI0271 IMPACT OF HLA-B27 STATUS ON CLINICAL OUTCOMES AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1448
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
https://doi.org/10.1007/s40744-021-00380-2
THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials
https://doi.org/10.1136/annrheumdis-2017-eular.4894
Documents that mention this clinical trial
THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2217
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials
https://doi.org/10.1007/s00296-021-05044-6
FRI0271 IMPACT OF HLA-B27 STATUS ON CLINICAL OUTCOMES AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1448
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
https://doi.org/10.1007/s40744-021-00380-2
Funding for this research was provided by:
novartis pharma ag
Article History
Received: 27 September 2021
Accepted: 28 October 2021
First Online: 13 November 2021
Declarations
:
: MD: Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma. UK: Grant/research support from: AbbVie, Amgen, Biogen, Hexal, Novartis, Pfizer, Consultant of: AbbVie, Eli Lilly and Company, Hexal, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Novartis, Pfizer, Roche, UCB. AK: Shareholder of: AbbVie, Amgen, Gilead, GSK, Pfizer Inc, Sanofi, Consultant of: AbbVie, Boehringer Ingelheim, Flexion, Genzyme, Gilead, Janssen, Novartis, Pfizer Inc, Regeneron, Sanofi, SUN Pharma Advanced Research, UCB, Paid instructor for: Celgene, Genzyme, Horizon, Merck, Novartis, Pfizer, Regeneron, Sanofi, Speakers bureau: AbbVie, Celgene, Flexion, Genzyme, Horizon, Merck, Novartis, Pfizer Inc, Regeneron, Sanofi. KP: Speakers bureau: AbbVie, BMS, MSD, UCB, Medac, Egis, Pfizer, Roche, Biogen, Novartis. SR, SM, EQF, BP, ZS: Employee and shareholder of Novartis.
: This study was conducted in accordance with the principles of the Declaration of Helsinki and all centers received approval from independent ethics committees or institutional review boards.